SCHEMBL3017749

SCHEMBL3017749

O=S(=O)(c1cccc(Cl)c1)C1CCN(c2nc(Cc3cccc(Br)c3)cs2)CC1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 2/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
KDM1A O60341 2/20 0.38
MAOA P21397 1/20 0.38
HTR2A P28223 3/20 0.37
HTR1A P08908 1/20 0.36
HTR7 P34969 1/20 0.36
MAPT P10636 2/20 0.34
GRM5 P41594 1/20 0.34
KCNH2 Q12809 2/20 0.34
CTPS1 P17812 2/20 0.34
HTR2C P28335 1/20 0.34
HTR6 P50406 2/20 0.33
POLB P06746 1/20 0.33
KMT2A Q03164 1/20 0.33
NPC1 O15118 1/20 0.33
NR3C1 P04150 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3005427 0.94 RAB9A (0.37) RAB9ASMN1; SMN2KDM1AMAOAHTR2A
SCHEMBL3003523 0.93 HTR2A (0.38) RAB9ASMN1; SMN2HTR2AKCNH2HTR2C
SCHEMBL3004812 0.92 RAB9A (0.36) RAB9ASMN1; SMN2KDM1AMAOAHTR2A
SCHEMBL3014841 0.92 EGFR (0.38) RAB9ASMN1; SMN2HTR2AHTR1AHTR7
SCHEMBL3013512 0.92 HTR2A (0.44) RAB9ASMN1; SMN2KDM1AMAOAHTR2A
SCHEMBL3008542 0.91 MAPT (0.36) RAB9ASMN1; SMN2KDM1AMAOAHTR2A
SCHEMBL3013306 0.91 RAB9A (0.42) RAB9ASMN1; SMN2HTR2AMAPTGRM5
SCHEMBL3018787 0.90 RAB9A (0.39) RAB9ASMN1; SMN2HTR2AMAPTGRM5
SCHEMBL3010771 0.90 HTR2A (0.34) RAB9ASMN1; SMN2HTR2AKCNH2HTR2C
SCHEMBL3003047 0.90 RAB9A (0.41) RAB9ASMN1; SMN2KDM1AHTR2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA RAB9A 2943/4885SMN1; SMN2 1/4885KDM1A 3548/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.